Condition 1: Novel Coronavirus(COVID-19). Condition 2: Intensive Care Unit Acquired Weakness. Clinically-epidemiologically diagnosed COVID-19 Critical illness myopathy
Conditions
Interventions
Intervention group: Patients return to the rehabilitation center three weeks after discharge from the hospital, and the rehabilitation program will be designed twice a week for two months (16 sessions
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Definitive diagnosis of Coronavirus based on Polymerase Chain Reaction (PCR) or lung CT Scan and expert opinion Intensive Care Unit Acquired Weakness (ICUAW) diagnosis based on the following criteria: - Total muscle strength points of 6 muscle groups bilaterally (Forearm flexion, wrist extension, Hip flexion, knee extension, Ankle dorsiflexion, Arm abduction) in manual examination according to Medical Research Council(MRC) criteria is less than 48 (out of 60 total points) - Normal consciousness based on Glasgow Coma Scale(GCS) (score 15 out of 15) - Opinion of an Anesthesiologist or Intensive Care Fellowship - History of hospitalization in ICU for more than 48 hours (with and without the need for Mechanical ventilation)
Exclusion criteria
Exclusion criteria: Loss of consciousness Uncontrolled hypertension means: resting systolic blood pressure> 180 mmHg and / or resting diastolic blood pressure> 110 mmHg Chest pain Uncontrolled sinus tachycardia (> 120 beats / min) or Sinus bradycardia (HR 30mmHg) Fever or Acute systemic disease Uncontrolled Diabetes Mellitus( DM) Severe Orthopedic or Neurological problems that prevent exercise Other metabolic conditions such as: Acute thyroiditis, Hyperkalemia, Hypokalemia and Hypovolemia (Until adequate treatment) Severe Psychological disorders Poor compliance Problem transporting the patient to the Rehabilitation Center Absence of the patient from rehabilitation sessions (More than 2 sessions)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Before the intervention and after the intervention (after 16th session). Method of measurement: World Health Organization Questionnaire.;Peripheral muscle force. Timepoint: Before the intervention and after the intervention (after 16th session). Method of measurement: Medical Research Council grading system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Inspiratory muscle strength. Timepoint: Before the intervention and after the intervention (after 16th session). Method of measurement: Assessment of Maximal inspiratory pressure(MIP) with Power Breath KH5 device.;Ability to perform activity of daily living(ADL). Timepoint: Before the intervention and after the intervention (after 16th session). Method of measurement: Katz Questionnaire.;Assess the level of anxiety and depression. Timepoint: Before the intervention and after the intervention (after 16th session). Method of measurement: Hospital Anxiety and Depression Scale(HADS) Questionnaire.;Evaluation of muscle mass changes. Timepoint: Before the intervention and after the intervention (after 16th session). Method of measurement: Bioelectrical impedance analysis device( BIA).;The degree of dyspnea. Timepoint: Before the intervention and after the intervention (after 16th session). Method of measurement: Modified Medical Research Council( MMRC) Dyspnea scale.;Evaluation of changes in Exercise capacity. Timepoint: Before the intervention and after the intervention (after 16th session). Method of measurement: 6 Minutes walk test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHanie Adib
Mazandaran University of Medical Sciences
Outcome results
None listed